Actively Recruiting
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Led by ETH Zurich · Updated on 2025-05-16
88
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
Sponsors
E
ETH Zurich
Lead Sponsor
U
University of Zurich
Collaborating Sponsor
AI-Summary
What this Trial Is About
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
CONDITIONS
Official Title
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with refractory or relapsed AML according to ELN2022 criteria.
- Age 18-70 years.
- Considered to be eligible for intensive chemotherapy.
- Written informed consent.
You will not qualify if you...
- Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations.
- Blast crisis after chronic myeloid leukemia (CML).
- Considered not eligible for intensive chemotherapy.
- Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).
- PCY not working / patient sample did not pass the QC steps of PCY.
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance.
- Legal incompetence or Subjects lacking capacity to provide informed consent.
- Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Inselspital Bern
Bern, Canton of Bern, Switzerland, 3010
Actively Recruiting
2
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland, 8091
Actively Recruiting
Research Team
B
Berend Snijder, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here